Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response

Journal of Thoracic Imaging

Volumn 26, Issue 2, 2011, Pages 132-146

  Truong, Mylene T ^a   Viswanathan, Chitra ^a   Erasmus, Jeremy J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Lung cancer; positron emission tomography computed tomography; staging

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M;

ADRENAL METASTASIS; BONE METASTASIS; BRAIN METASTASIS; BRONCHUS BIOPSY; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; HUMAN; LIVER METASTASIS; LUNG CANCER; LUNG LOBECTOMY; LUNG NODULE; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SCINTISCANNING; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MEDIASTINOSCOPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; PROGNOSIS; SENSITIVITY AND SPECIFICITY; THORACOTOMY; TREATMENT PLANNING; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; CONTRAST MEDIA; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM STAGING; PROGNOSIS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 79955567637     PISSN: 08835993     EISSN: 15360237     Source Type: Journal    
DOI: 10.1097/RTI.0b013e3182128704     Document Type: Conference Paper

References (130)

1. Adams MC TT, Wilson JM, Wong TZ. A systematic review of factors affecting accuracy of SUV measurements. Am J Roentgenol. 2010;195:310-320.
2. Lowe VJ, Hoffman JM, DeLong DM, et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med. 1994;35:1771-1776. (Pubitemid 24346796)
3. Costa DC, Visvikis D, Crosdale I, et al. Positron emission and computed X-ray tomography: a coming together. Nucl Med Commun. 2003;24:351-358.
4. Cook GJ, Wegner EA, Fogelman I. Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med. 2004;34:122-133. (Pubitemid 38375467)
5. De Wever W, Stroobants S, Coolen J, et al. Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J. 2009;33: 201-212.
6. Beyer T, Antoch G, Blodgett T, et al. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging. 2003;30:588-596. (Pubitemid 36559838)
7. Osman MM, Cohade C, Nakamoto Y, et al. Respiratory motion artifacts on PET emission images obtained using CT attenuation correction on PET-CT. Eur J Nucl Med Mol Imaging. 2003;30:603-606. (Pubitemid 36559840)
8. Goerres GW, Burger C, Kamel E, et al. Respiration-induced attenuation artifact at PET/CT: technical considerations. Radiology. 2003;226:906-910. (Pubitemid 36259170)
9. Pan T, Mawlawi O, Nehmeh SA, et al. Attenuation correction of PET images with respiration-averaged CT images in PET/ CT. J Nucl Med. 2005;46:1481-1487. (Pubitemid 46173260)
10. Truong MT, Pan T, Erasmus JJ. Pitfalls in integrated CT-PET of the thorax: implications in oncologic imaging. J Thorac Imaging. 2006;21:111-122. (Pubitemid 43904259)
11. Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001;285: 914-924. (Pubitemid 32171553)
12. Rohren EM, Lowe VJ. Update in PET imaging of nonsmall cell lung cancer. Semin Nucl Med. 2004;34:134-153. (Pubitemid 38375468)
13. Yi CA, Lee KS, Kim BT, et al. Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med. 2006;47: 443-450. (Pubitemid 46768487)
14. Bryant AS, Cerfolio RJ. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg. 2006;82:1016-1020.
15. Nomori H, Watanabe K, Ohtsuka T, et al. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer. 2004;45:19-27. (Pubitemid 38757828)
16. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of PET in lung nodules (PIOPILN). J Clin Oncol. 1998;16:1075-1084. (Pubitemid 28108743)
17. Herder GJ, Golding RP, Hoekstra OS, et al. The performance of (18)F-fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodules. Eur J Nucl Med Mol Imaging. 2004;31:1231-1236. (Pubitemid 39222486)
18. Erasmus JJ, McAdams HP, Patz JEF, et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. Am J Roentgenol. 1998;170:1369-1373. (Pubitemid 28210961)
19. Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med. 1998;39:1016-1020. (Pubitemid 28270118)
20. Sabloff BS, Truong MT, Wistuba II, et al. Bronchioalveolar cell carcinoma: radiologic appearance and dilemmas in the assessment of response. Clin Lung Cancer. 2004;6:108-112. (Pubitemid 39440208)
21. Cheran SK, Nielsen ND, Patz EF Jr. False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications. Am J Roentgenol. 2004;182:1129-1132. (Pubitemid 38525502)
22. Asad S, Aquino SL, Piyavisetpat N, et al. False-positive FDG positron emission tomography uptake in nonmalignant chest abnormalities. Am J Roentgenol. 2004;182:983-989. (Pubitemid 38391663)
23. Tan BB, Flaherty KR, Kazerooni EA, et al. The solitary pulmonary nodule. Chest. 2003;123:89S-96S. (Pubitemid 36135706)
24. Gould MK, Ananth L, Barnett PG. A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. Chest. 2007;131:383-388. (Pubitemid 46280396)
25. Gould MK, Sanders GD, Barnett PG, et al. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Ann Intern Med. 2003;138:724-735. (Pubitemid 38139236)
26. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22: 330-353. (Pubitemid 41095099)
27. Verboom P, Van Tinteren H, Hoekstra OS, et al. Costeffectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging. 2003;30:1444-1449. (Pubitemid 37356109)
28. Lardinois D, Weder W, Hany TF, et al. Staging of non-smallcell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348: 2500-2507. (Pubitemid 36706537)
29. Verhagen AF, Bootsma GP, Tjan-Heijnen VC, et al. FDGPET in staging lung cancer: how does it change the algorithm? Lung Cancer. 2004;44:175-181. (Pubitemid 38482050)
30. Reed CE, Harpole DH, Posther KE, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003;126:1943-1951. (Pubitemid 38020756)
31. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol. 1998;16:2142-2149. (Pubitemid 28265051)
32. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254-261. (Pubitemid 30490393)
33. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology. 2003;229:526-533. (Pubitemid 37310842)
34. van Baardwijk A, Baumert BG, Bosmans G, et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev. 2006;32: 245-260. (Pubitemid 44502002)
35. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111:1718-1723. (Pubitemid 27260108)
36. Prenzel KL, Monig SP, Sinning JM, et al. Lymph node size and metastatic infiltration in non-small cell lung cancer. Chest. 2003;123:463-467. (Pubitemid 36269431)
37. De Leyn P, Vansteenkiste J, Cuypers P, et al. Role of cervical mediastinoscopy in staging of non-small cell lung cancer without enlarged mediastinal lymph nodes on CT scan. Eur J Cardiothorac Surg. 1997;12:706-712. (Pubitemid 28035533)
38. Choi YS, Shim YM, Kim J, et al. Mediastinoscopy in patients with clinical stage I non-small cell lung cancer. Ann Thorac Surg. 2003;75:364-366. (Pubitemid 36184471)
39. Toloza EM, Harpole L, Detterbeck F, et al. Invasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003;123:157S-166S. (Pubitemid 36135713)
40. Jeon TY, Lee KS, Yi CA, et al. Incremental value of PET/CT Over CT for mediastinal nodal staging of non-small cell lung cancer: comparison between patients with and without idiopathic pulmonary fibrosis. Am J Roentgenol. 2010;195:370-376.
41. Birim O, Kappetein AP, Stijnen T, et al. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg. 2005;79:375-382. (Pubitemid 40037519)
42. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with nonsmall- cell lung cancer: a meta-analysis. Ann Intern Med. 2003; 139:879-892.
43. Yasufuku K, Nakajima T, Motoori K, et al. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest. 2006;130:710-718. (Pubitemid 44423601)
44. de Langen AJ, Raijmakers P, Riphagen I, et al. The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg. 2006; 29:26-29. (Pubitemid 41831343)
45. Dietlein M, Weber K, Gandjour A, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med. 2000;27: 1598-1609.
46. Scott WJ, Shepherd J, Gambhir SS. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg. 1998;66:1876-1885. (Pubitemid 29087176)
47. Quint LE, Tummala S, Brisson LJ, et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg. 1996;62:246-250. (Pubitemid 26239872)
48. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359:1388-1393.
49. MacManus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys. 2001;50:287-293. (Pubitemid 32472257)
50. Schrevens L, Lorent N, Dooms C, et al. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist. 2004;9:633-643. (Pubitemid 39546404)
51. Viney RC, Boyer MJ, King MT, et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol. 2004;22:2357-2362. (Pubitemid 41115392)
52. Lardinois D, Weder W, Roudas M, et al. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol. 2005;23:6846-6853.
53. Oliver TW Jr, Bernardino ME, Miller JI, et al. Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma. Radiology. 1984;153:217-218. (Pubitemid 14043411)
54. Remer EM, Obuchowski N, Ellis JD, et al. Adrenal mass evaluation in patients with lung carcinoma: a cost-effectiveness analysis. Am J Roentgenol. 2000;174:1033-1039. (Pubitemid 30179999)
55. Yun M, Kim W, Alnafisi N, et al. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med. 2001;42:1795-1799. (Pubitemid 34016347)
56. Erasmus JJ, Patz EF, McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma by using 18F-fluorodeoxyglucose positron emission tomography. Am J Roentgenol. 1997;168:1357-1360.
57. Blake MA, Slattery JM, Kalra MK, et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy-initial experience. Radiology. 2006;238:970-977. (Pubitemid 43289929)
58. Metser U, Miller E, Lerman H, et al. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med. 2006;47:32-37. (Pubitemid 46768509)
59. Yokoi K, Kamiya N, Matsuguma H, et al. Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI. Chest. 1999;115:714-719. (Pubitemid 29129950)
60. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003;123:137S-146S. (Pubitemid 36135711)
61. Silvestri GA, Tanoue LT, MargolisML, et al. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest. 2003;123:147S-156S. (Pubitemid 36135712)
62. Salvatierra A, Baamonde C, Llamas JM, et al. Extrathoracic staging of bronchogenic carcinoma. Chest. 1990;97:1052-1058. (Pubitemid 20166789)
63. Michel F, Soler M, Imhof E, et al. Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning. Thorax. 1991;46:469-473.
64. Silvestri GA, Littenberg B, Colice GL. The clinical evaluation for detecting metastatic lung cancer: a meta-analysis. Am J Respir Crit Care Med. 1995;152:225-230.
65. Taira AV, Herfkens RJ, Gambhir SS, et al. Detection of bone metastases: assessment of integrated FDG PET/CT imaging. Radiology. 2007;243:204-211. (Pubitemid 46579712)
66. Dwamena BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990's: meta-analytic comparison of PET and CT. Radiology. 1999;213:530-536. (Pubitemid 29510603)
67. Erasmus JJ, McAdams HP, Rossi SE, et al. FDG PET of pleural effusions in patients with non-small cell lung cancer. Am J Roentgenol. 2000;175:245-249. (Pubitemid 30415572)
68. Schaffler GJ, Wolf G, Schoellnast H, et al. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET. Radiology. 2004;231:858-865. (Pubitemid 38668109)
69. Prakash P, Kalra MK, Sharma A, et al. FDG PET/CT in assessment of pulmonary lymphangitic carcinomatosis. Am J Roentgenol. 2009;194:231-236.
70. Detterbeck FC, Jantz MA, Wallace M, et al. Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:202S-220S. (Pubitemid 47502808)
71. Hanin FX, Lonneux M, Cornet J, et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg. 2008;33:819-823.
72. Goodgame B, Pillot GA, Yang Z, et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol. 2008;3:130-134. (Pubitemid 351323186)
73. Davies A, Tan C, Paschalides C, et al. FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. Lung Cancer. 2007;55:75-78. (Pubitemid 46038876)
74. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22:3255-3260. (Pubitemid 41103680)
75. Borst GR, Belderbos JS, Boellaard R, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer. 2005;41:1533-1541. (Pubitemid 40981834)
76. Higashi K, Ueda Y, Arisaka Y, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med. 2002;43:39-45. (Pubitemid 34101186)
77. Ohtsuka T, Nomori H, Watanabe K, et al. Prognostic significance of [(18)F] fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer. 2006;107:2468-2473. (Pubitemid 44748531)
78. Patz EF Jr, Connolly J, Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. Am J Roentgenol. 2000;174:769-774. (Pubitemid 30126260)
79. Berghmans T, Dusart M, Paesmans M, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol. 2008;3:6-12.
80. Ahuja V, Coleman RE, Herndon J, et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer. 1998;83:918-924. (Pubitemid 28401925)
81. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importane of the standardized uptake value on (18)F-fluoro-2-deoxy-gluxose-positron emission tomography scan in non-small-cell lung cancer. An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17: 3201-3206. (Pubitemid 29470652)
82. Dhital K, Saunders CA, Seed PT, et al. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg. 2000;18:425-428.
83. Jeong HJ, Min JJ, Park JM, et al. Determination of the prognostic value of [(18)F] fluorodeoxyglucose uptake by using positron emission tomography in patients with nonsmall cell lung cancer. Nucl Med Commun. 2002;23:865-870.
84. Cerfolio RJ, Bryant AS, Ohja B, et al. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005;130:151-159. (Pubitemid 40941684)
85. Decoster L, Schallier D, Everaert H, et al. Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography [(18)FDG-PET], after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2008;62:55-61.
86. MacManus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2003;21:1285-1292. (Pubitemid 46606405)
87. Hoang JK, Hoagland LF, Coleman RE, et al. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol. 2008;26: 1459-1464.
88. Aristei C FL, Palumbo B, Tarducci R. PET and PET-CT in radiation treatment planning for lung cancer. Expert Rev Anticancer Ther. 2010;10:571-584.
89. MacManus M, Nestle U, Rosenzweig KE, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol. 2009;91:85-94.
90. Vansteenkiste J, Fischer BM, Dooms C, et al. Positronemission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol. 2004;5: 531-540. (Pubitemid 39194041)
91. Mac Manus MP, Wong K, Hicks RJ, et al. Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys. 2002;52:351-361. (Pubitemid 34170842)
92. Mac Manus MP, Hicks RJ, Ball DL, et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer. 2001;92:886-895. (Pubitemid 32783077)
93. Pommier P, Touboul E, Chabaud S, et al. Impact of (18)FFDG PET on treatment strategy and 3D radiotherapy planning in non-small cell lung cancer: a prospective multicenter study. Am J Roentgenol. 2010;195:350-355.
94. Bradley J, Thorstad WL, Mutic S, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;59:78-86. (Pubitemid 38501510)
95. Graeter TP, Hellwig D, Hoffmann K, et al. Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. Ann Thorac Surg. 2003;75:231-235; discussion 235-236.
96. Mac Manus MP, Hicks RJ. Impact of PET on radiation therapy planning in lung cancer. Radiol Clin North Am. 2007; 45:627-638, v. (Pubitemid 47238387)
97. Nestle U, Walter K, Schmidt S, et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys. 1999;44:593-597. (Pubitemid 29258434)
98. Sekine I, Tamura T, Kunitoh H, et al. Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer. Ann Oncol. 1999;10:731-733. (Pubitemid 29342381)
99. Duhaylongsod FG, Lowe VJ, Patz EF Jr, et al. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg. 1995;60:1348-1352.
100. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-1782. (Pubitemid 29512308)
101. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993;34:414-419. (Pubitemid 23075381)
102. Watanabe K, Nomori H, Ohtsuka T, et al. [F-18] Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. Jpn J Clin Oncol. 2006;36:403-409. (Pubitemid 44304797)
103. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol. 1998;9:1193-1198. (Pubitemid 28552808)
104. Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2- deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:8362-8370.
105. De Leyn P, Stroobants S, De Wever W, et al. Prospective comparative study of integrated positron emission tomography- computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopyproven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol. 2006;24:3333-3339. (Pubitemid 46638886)
106. Eschmann SM, Friedel G, Paulsen F, et al. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2007;55:165-171. (Pubitemid 46074221)
107. Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg. 2006;131:1229-1235. (Pubitemid 43792421)
108. Pottgen C, Levegrun S, Theegarten D, et al. Value of 18Ffluoro- 2-deoxy-D-glucose-positron emission tomography/ computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res. 2006;12: 97-106. (Pubitemid 43166182)
109. Eschmann SM, Friedel G, Paulsen F, et al. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III nonsmall cell lung cancer. Eur J Nucl Med Mol Imaging. 2007; 34:463-471. (Pubitemid 46426996)
110. Ohtsuka T, Nomori H, Ebihara A, et al. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 2006;12:89-94.
111. Poettgen C, Theegarten D, Eberhardt W, et al. Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer. Oncology. 2007;73:316-323. (Pubitemid 351862022)
112. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
113. Deichen JT, Prante O, Gack M, et al. Uptake of [18F]fluorodeoxyglucose in human monocyte-macrophages in vitro. Eur J Nucl Med Mol Imaging. 2003;30:267-273. (Pubitemid 36686846)
114. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21:2651-2657. (Pubitemid 46606307)
115. Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47:1059-1066. (Pubitemid 46939960)
116. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(suppl 1):122S-150S.
117. Campione A, Ligabue T, Luzzi L, et al. Late outcome and perioperative complications for surgery of locally recurrent bronchogenic carcinoma. J Cardiovasc Surg (Torino). 2005; 46:515-518. (Pubitemid 41819429)
118. Watanabe Y, Shimizu J, Oda M, et al. Second surgical intervention for recurrent and second primary bronchogenic carcinomas. Scand J Thorac Cardiovasc Surg. 1992;26:73-78.
119. Milton DT, Miller VA. Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancer. Semin Oncol. 2005;32:299-314. (Pubitemid 40834487)
120. Curran WJ Jr, Herbert SH, Stafford PM, et al. Should patients with post-resection locoregional recurrence of lung cancer receive aggressive therapy? Int J Radiat Oncol Biol Phys. 1992;24:25-30.
121. Frank A, Lefkowitz D, Jaeger S, et al. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys. 1995;32:1495-1512.
122. Ryu JS, Choi NC, Fischman AJ, et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer. 2002;35:179-187. (Pubitemid 34136096)
123. Inoue T, Kim E, Komaki R, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med. 1995;36: 788-793.
124. Hicks RJ, Kalff V, MacManus MP, et al. The utility of (18)FFDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med. 2001;42:1605-1613. (Pubitemid 33131318)
125. Bury T, Corhay JL, Duysinx B, et al. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J. 1999;14:1376-1380. (Pubitemid 30019536)
126. Hellwig D, Groschel A, Graeter TP, et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2006;33:13-21. (Pubitemid 41785304)
127. Keidar Z, Haim N, Guralnik L, et al. PET/CT using 18FFDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med. 2004;45: 1640-1646. (Pubitemid 47618469)
128. Hicks RJ, Mac Manus MP, Matthews JP, et al. Early FDGPET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys. 2004;60:412-418. (Pubitemid 39233459)
129. Bradley JD, Dehdashti F, Mintun MA, et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol. 2004;22:3248-3254. (Pubitemid 41103679)
130. Brink I, Schumacher T, Mix M, et al. Impact of [18F]FDGPET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2004;31:1614-1620. (Pubitemid 40104607)